Post-approval studies (Phase 4)Ended earlyNCT01606800
What this trial is testing
Efficacy and Safety of Short Course Therapy With Peginterferon Alpha-2b (PEG-IFN Alfa-2b) and Ribavirin (RBV) for Chronic Hepatitis C (Genotype 4) Participants Achieving a Rapid Virological Response at Week 4 of Treatment (MK-8908B-059)
Who this might be right for
Hepatitis C, Chronic
Merck Sharp & Dohme LLC 45